Anti-Inflammatory Treatment With Colchicine in Stable Chronic Heart Failure

JACC: Heart Failure - Tập 2 Số 2 - Trang 131-137 - 2014
Spyridon Deftereos1,2, Γεώργιος Γιαννόπουλος1,3,2, Vasiliki Panagopoulou1, Georgios Bouras1, Konstantinos Raisakis1, Charalampos Kossyvakis1,3, Sofia Karageorgiou1, Charalampos Papadimitriou1, Maria Vastaki1, Andreas Kaoukis1, Christos Angelidis1, Stamatina Pagoni4, Vlasios Pyrgakis1, Dimitrios Alexopoulos5, Antonis S. Manolis6, Christodoulos Stefanadis6, Michael Cleman2
1Department of Cardiology, Athens General Hospital “G. Gennimatas,” Athens, Greece
2Section of Cardiovascular Medicine, Yale University School of Medicine, Yale University, New Haven, Connecticut
3Hellenic Center of Disease Control and Prevention Athens, Greece
4Third Department of Internal Medicine, Athens General Hospital "G. Gennimatas," Athens, Greece
5Department of Cardiology, University of Patras Medical School, Patras, Greece
6First Department of Cardiology, University of Athens Medical School, Athens, Greece

Tóm tắt

Từ khóa


Tài liệu tham khảo

Mann, 1994, Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines, Chest, 105, 897, 10.1378/chest.105.3.897

Rauchhaus, 2000, Plasma cytokine parameters and mortality in patients with chronic heart failure, Circulation, 102, 3060, 10.1161/01.CIR.102.25.3060

Deswal, 2001, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST), Circulation, 103, 2055, 10.1161/01.CIR.103.16.2055

Mann, 2005, Targeted anticytokine therapy and the failing heart, Am J Cardiol, 95, 9C, 10.1016/j.amjcard.2005.03.007

Hofmann, 2013, How can we cure a heart “in flame”? A translational view on inflammation in heart failure, Basic Res Cardiol, 108, 356, 10.1007/s00395-013-0356-y

Heymans, 2009, Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 11, 119, 10.1093/eurjhf/hfn043

Gullestad, 2005, Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches, Am J Cardiol, 95, 17C, 10.1016/j.amjcard.2005.03.008

Deftereos, 2013, Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients, J Am Coll Cardiol, 61, 1679, 10.1016/j.jacc.2013.01.055

Deftereos, 2012, Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study, J Am Coll Cardiol, 60, 1790, 10.1016/j.jacc.2012.07.031

Nidorf, 2013, Low-dose colchicine for secondary prevention of cardiovascular disease, J Am Coll Cardiol, 61, 404, 10.1016/j.jacc.2012.10.027

Imazio, 2011, Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy, Circulation, 124, 2290, 10.1161/CIRCULATIONAHA.111.026153

Crackower, 2002, Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways, Cell, 110, 737, 10.1016/S0092-8674(02)00969-8

Patrucco, 2004, PI3K gamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects, Cell, 118, 375, 10.1016/j.cell.2004.07.017

Weber, 1997, Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation, Circulation, 96, 4065, 10.1161/01.CIR.96.11.4065

Hudson, 2006, Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial, J Am Coll Cardiol, 48, 15, 10.1016/j.jacc.2006.02.055

Schellings, 2004, Matricellular proteins in the heart: possible role during stress and remodeling, Cardiovasc Res, 64, 24, 10.1016/j.cardiores.2004.06.006

Schroen, 2004, Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy, Circ Res, 95, 515, 10.1161/01.RES.0000141019.20332.3e

Van Tassell, 2012, Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure, PLoS One, 7, e33438, 10.1371/journal.pone.0033438

Chung, 2003, Circulation, 107, 3133, 10.1161/01.CIR.0000077913.60364.D2

Mann, 2004, Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL), Circulation, 109, 1594, 10.1161/01.CIR.0000124490.27666.B2

Abbate, 2010, Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study), Am J Cardiol, 105, 1371, 10.1016/j.amjcard.2009.12.059

Abbate, 2013, Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study], Am J Cardiol, 111, 1394, 10.1016/j.amjcard.2013.01.287

Terkeltaub, 2009, Colchicine update: 2008, Semin Arthritis Rheum, 38, 411, 10.1016/j.semarthrit.2008.08.006

Deftereos, 2013, Colchicine and the heart: pushing the envelope, J Am Coll Cardiol, 62, 1817, 10.1016/j.jacc.2013.08.726

Sabouraud, 1994, Binding of colchicine and thiocolchicoside to human serum proteins and blood cells, Int J Clin Pharmacol Ther, 32, 429

Chappey, 1993, Colchicine disposition in human leukocytes after single and multiple oral administration, Clin Pharmacol Ther, 54, 360, 10.1038/clpt.1993.161